N-acetylcysteine Enteric Coating for Enhanced Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
N-acetylcysteine (NAC) suffers from low bioavailability and short terminal half-life, requiring high dosing regimens or constant administration, and its slow-release formulations reduce oral availability, necessitating innovative formulations to enhance bioavailability and terminal half-life.
Innovation Solution
Modified release solid dosage forms of NAC with a coating layer that solubilizes in the duodenum or at a pH greater than 5.4, preventing release in the gastrointestinal tract, potentially including a second compound with a nitrone moiety like 2,4-disulfophenyl-N-tert-butyl nitrone, to increase systemic absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NAC is administered in high dosing regimens or constant administration to overcome low bioavailability and short terminal half-life, then therapeutic effect is maintained, but patient compliance decreases and treatment complexity increases
Solution Approach 1:
The patent segments the NAC delivery system into multiple functional components: an enteric coating layer that protects NAC from gastric degradation, a controlled release matrix that modulates dissolution rate, and a capsule formulation that enables convenient single-dose administration. This segmentation allows the drug to survive stomach conditions and release systematically, maintaining therapeutic levels without requiring frequent dosing.
Solution Approach 2:
The enteric coating is applied in advance to protect NAC from acidic degradation before it reaches the intestine. The controlled release matrix is pre-formulated to regulate drug release kinetics. These preliminary actions ensure that NAC is protected and released optimally, eliminating the need for complex dosing schedules and improving patient compliance.
2Duration of action of moving object
If slow-release formulation is used to extend terminal half-life, then dosing frequency is reduced, but oral availability of NAC decreases
Solution Approach 1:
The patent applies different functional properties to different parts of the formulation: the enteric coating provides acid resistance specifically in the gastric environment, while the controlled release matrix provides sustained dissolution in the intestinal environment. This local differentiation of properties allows the formulation to protect NAC where needed while ensuring adequate release and absorption in the appropriate location, thereby extending half-life without sacrificing oral availability.
Solution Approach 2:
The formulation changes the physical-chemical parameters of NAC delivery by using pH-dependent solubility characteristics. The enteric coating remains intact at low gastric pH but dissolves at higher intestinal pH, enabling the drug to be protected during gastric transit and released in the intestine where absorption occurs. This parameter-based control extends terminal half-life while maintaining oral availability.
3Stability of the object's composition
If enteric coating is applied to protect NAC from gastric degradation, then stability in stomach is improved, but release mechanism becomes more complex
Solution Approach 1:
The enteric coating acts as an intermediary layer between the acidic gastric environment and the NAC core. This coating layer is specifically designed to be stable in acid but soluble in the higher pH of the intestine, thereby mediating the transition of NAC through the gastrointestinal tract. The use of well-established enteric coating materials and standardized application techniques keeps the formulation complexity manageable despite the added protection mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified release dosage forms significantly increase systemic exposure of NAC, allowing for reduced dosing frequency and increased therapeutic effect, as demonstrated by higher AUC values and extended half-life, effectively treating conditions such as acute acoustic trauma and hearing loss.
Implementation Method 1
the coating layer solubilizes in the mammal's duodenum and prevents release of the first compound in a gastrointestinal tract before a mammal's duodenum upon oral administration, or wherein the coating layer solubilizes at a pH of greater than 5.4 in a physiological environment
Implementation Method 2
a second compound that is a pharmaceutically acceptable compound capable of forming a radical adduct
Data Source
AI summary
Disclosed herein are compositions comprising a first compound that is N-acetylcysteine or a salt thereof, optionally a second compound that is a pharmaceutically acceptable compound capable of forming a radical adduct; and a coating layer encapsulating at least the first compound. Also disclosed are methods of use and manufacture.